- CH₣26.87bn
- CH₣30.04bn
- $10.40bn
Brief: Alcon Acquires Neurotech And Encelto, The Only FDA-Approved Treatment For Mactel Type 2
Swiss stocks - Factors to watch on October 19
Brief: FDA Approves Alcon’S BRYTL Eye Drops
Advisory: Alert incorrectly tagged to Omega Interactive Technologies withdrawn
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Alcon AG Prices EUR 500 Million 3.875% Senior Notes Due 2033
Swiss stocks - Factors to watch on August 12
European stocks pause near record highs as earnings optimism offsets energy supply concerns
Brief: Alcon CFO On Call - Higher Gross Margin In Q3 Due To Tariff Refunds
European stocks pause near record highs as oil rally keeps investors cautious
Eye care company Alcon raises margin outlook, shares jump (updated)
Live Markets: Before the bell: Europe set for subdued start as oil tops $89
Alcon shares seen rising after outlook hike
Eye care company Alcon raises profitability outlook, cuts tariff hit estimate
Swiss stocks - Factors to watch on August 11
Alcon lifts 2026 outlook after Q2 adjusted EPS beat estimates
Swiss stocks - Factors to watch on July 7
Swiss eye care firm Alcon's quarterly revenue rises less than expected (updated)